These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 18256322)

  • 1. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
    Larson RA; Druker BJ; Guilhot F; O'Brien SG; Riviere GJ; Krahnke T; Gathmann I; Wang Y;
    Blood; 2008 Apr; 111(8):4022-8. PubMed ID: 18256322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
    Guilhot F; Hughes TP; Cortes J; Druker BJ; Baccarani M; Gathmann I; Hayes M; Granvil C; Wang Y
    Haematologica; 2012 May; 97(5):731-8. PubMed ID: 22315495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
    Sohn SK; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Yoon SS; Kim H; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Moon JH; Park SY
    Leuk Lymphoma; 2011 Jun; 52(6):1024-9. PubMed ID: 21463107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC.
    Koren-Michowitz M; Volchek Y; Naparstek E; Gavish I; Levi I; Rowe JM; Shimoni A; Nagler A
    Hematol Oncol; 2012 Dec; 30(4):200-5. PubMed ID: 22241698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Acta Haematol; 2012; 127(4):221-7. PubMed ID: 22473087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
    Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
    Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
    Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
    Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
    J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
    Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
    Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
    Hochhaus A; Druker B; Sawyers C; Guilhot F; Schiffer CA; Cortes J; Niederwieser DW; Gambacorti-Passerini C; Stone RM; Goldman J; Fischer T; O'Brien SG; Reiffers JJ; Mone M; Krahnke T; Talpaz M; Kantarjian HM
    Blood; 2008 Feb; 111(3):1039-43. PubMed ID: 17932248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
    Jabbour E; Kantarjian H; Ghanem H; O'Brien S; Quintas-Cardama A; Garcia-Manero G; Cardenas M; Cortes J
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):302-6. PubMed ID: 23318257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
    Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
    Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
    Pavlovsky C; Egorin MJ; Shah DD; Beumer JH; Rogel S; Pavlovsky S
    Pharmacotherapy; 2009 Sep; 29(9):1152-6. PubMed ID: 19698017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
    Chen C; Wang W; Xu CG; Hou M; Wang LQ; Liu CF; Song Q; Ji CY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):450-3. PubMed ID: 22213863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
    Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.
    Kawaguchi T; Hamada A; Hirayama C; Nakashima R; Nambu T; Yamakawa Y; Watanabe H; Horikawa K; Mitsuya H; Saito H
    Int J Hematol; 2009 Jun; 89(5):642-8. PubMed ID: 19396513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase.
    Sharma SK; Kumar S; Vijayakumar AR; Seth T; Mishra P; Mahapatra M; Sazawal S; Velpandian T; Saxena R
    J Cancer Res Ther; 2014; 10(2):305-8. PubMed ID: 25022382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.